R&D in High-Value-Added New Products, Pharmaceuticals and Fine Chemicals
First written in FY2016. 30 of 33 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2023: 2 of 10 companies on the "Worse" side.
1 other company's latest entry also says "Reframed".
- FY2026ReframedAnnual report
「We focus our R&D efforts on 3 fields in the fine chemicals business, amino acids, chemical products and pharmaceuticals, to create high-value-added new products.」
The company identified amino acids, chemical products and pharmaceuticals as the 3 R&D fields, and specified its focus on applying and further developing strategic technologies and developing new products related to pharmaceuticals, IT, polymers and functional materials. R&D expenses for the fiscal year were ¥618 million. - 2026-05-19AdvancedManagement Planning
「We will also strengthen cooperation with other companies and universities in order to contribute to the development of innovative pharmaceuticals.」
In pharmaceutical research and development and technological innovation, the company explicitly stated that it would strengthen cooperation with other companies and universities and pursue contract opportunities involving highly potent active pharmaceutical ingredients and regenerative medicine products. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the interim accounting period were ¥318 million. There were no material changes in the status of the company's R&D activities during the interim accounting period.」
The company continued its R&D activities and disclosed interim-period R&D expenses of ¥318 million. It stated that there were no material changes in the status of its R&D activities, and no change in its R&D policy for the pharmaceutical and fine chemicals fields or new achievements were indicated. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim accounting period were ¥203 million. There were no material changes in the status of the company's R&D activities during the interim accounting period.」
The company continued its R&D activities and disclosed interim-period R&D expenses of ¥203 million. It stated that there were no material changes in the status of its R&D activities, and no change in its R&D policy for the pharmaceutical and fine chemicals fields or new achievements were indicated. - FY2024RestatedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products. In the pharmaceutical-related field, we are focusing on R&D aimed at manufacturing generic APIs and undertaking contract manufacturing of APIs and key intermediates for new drugs, including investigational drugs, and existing drugs. In the fine chemicals field, while researching the application and further development of strategic technologies such as reduction reactions, Grignard reactions and biological reactions, we are pursuing R&D centered on amino acid derivatives, pyridine, piperidine and quinuclidine derivatives, and organosilicon compounds, with a view to the IT-related, polymer-related and functional materials fields. Total R&D expenses for the fiscal year were ¥639 million.」
The company continued its R&D policy centered on the pharmaceutical and fine chemicals fields, specifying contract manufacturing, strategic technologies, functional materials and other areas. R&D expenses were ¥639 million for the fiscal year, but no completion of the policy or new achievement milestones were indicated. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥495 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥495 million for the cumulative third quarter. It stated that there were no material changes in the status of its R&D activities, and no change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥339 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥339 million for the cumulative second quarter. It stated that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥116 million.」
The company continued its R&D activities, including in the pharmaceutical and fine chemicals fields. R&D expenses for the cumulative first quarter were ¥116 million, and no material change in its R&D policy or new achievements were indicated. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥472 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed R&D expenses of ¥472 million for the cumulative third quarter and stated that there were no material changes in the status of its R&D activities. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥375 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥375 million for the cumulative second quarter. It stated that there were no material changes in the status of its R&D activities, and no change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥130 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥130 million for the cumulative first quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2022RestatedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products.」
The company continued its R&D policy covering generic APIs, APIs and key intermediates for new and existing drugs, various derivatives, organosilicon compounds and other products, and disclosed R&D expenses of ¥377 million for the fiscal year. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥199 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed R&D expenses of ¥199 million and stated that there were no material changes in the status of its R&D activities. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥99 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥99 million for the cumulative second quarter. It stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥59 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥59 million for the cumulative first quarter. No material change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥182 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥182 million for the cumulative third quarter. No explanation of material changes in its R&D policy was provided, and no change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥106 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥106 million for the cumulative second quarter. The company stated that there were no material changes in the status of its R&D activities, and no change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥72 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥72 million for the cumulative first quarter, down from ¥267 million in the same period of the previous year. No explanation of material changes in the status of its R&D activities or change in its R&D policy was indicated. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥468 million.」
The company continued its R&D activities, including in the pharmaceutical and fine chemicals fields, and disclosed R&D expenses of ¥468 million for the cumulative third quarter. No change in its R&D policy or new achievements were indicated. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥398 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities, including in the pharmaceutical and fine chemicals fields, and disclosed R&D expenses of ¥398 million for the cumulative second quarter. The company stated that there were no material changes in the status of its R&D activities. - FY2019RestatedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products. Total R&D expenses for the fiscal year were ¥345 million.」
The company continued its R&D policy centered on the pharmaceutical and fine chemicals fields and disclosed R&D expenses of ¥345 million for the fiscal year. No new R&D objectives or achievements were indicated. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥264 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥264 million for the cumulative third quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields or new achievements were indicated. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥213 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥213 million for the cumulative second quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields or new achievements were indicated. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥146 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥146 million for the cumulative first quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2018RestatedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products.」
The company continued its R&D policy for the pharmaceutical-related and fine chemicals fields and disclosed total R&D expenses of ¥338 million for the fiscal year. No new R&D objectives or achievements were indicated. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥291 million.」
The company continued its R&D activities, including in the pharmaceutical and fine chemicals fields, and disclosed R&D expenses of ¥291 million for the cumulative third quarter. No change in its R&D policy was indicated. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥188 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥188 million for the cumulative second quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥85 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥85 million for the cumulative first quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2017RestatedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products.」
The company continued its R&D policy for the pharmaceutical and fine chemicals fields and disclosed total R&D expenses of ¥404.289 million for the fiscal year. No new R&D objectives were indicated. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥374.825 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥374.825 million for the cumulative third quarter. No change in its R&D policy for the pharmaceutical and fine chemicals fields was indicated. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥288.432 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥288.432 million for the cumulative second quarter. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥219.788 million.」
The company continued its R&D activities, disclosing R&D expenses of ¥219.788 million for the first quarter, including the pharmaceutical and fine chemicals fields. - FY2016First statedAnnual report
「We focus on R&D related to the pharmaceutical and fine chemicals fields, with the aim of creating high-value-added new products.」
R&D expenses of ¥407.312 million were recorded, covering generic APIs, APIs and key intermediates for new and existing drugs, various derivatives, organosilicon compounds and other products.